Biocon Limited
BIOCON
Rank in Stocks
#3387
Biocon Limited functions as a biopharmaceutical firm, engaged in the production... Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Share Price
$3.76
Last synced: 2026-10-19
Market Cap
$5.14B
Change (1 day)
-2.11%
Change (1 year)
-9.31%
Country
IN
Trade Biocon Limited (BIOCON)
Category
Healthcare
P/E ratio for Biocon Limited (BIOCON)
P/E ratio as of October 2026 TTM: 104.29
According to Biocon Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 104.29. At the end of 2024 the company had a P/E ratio of 31.54.
P/E ratio history for Biocon Limited from 2004 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 104.29 | 160.21% |
| 2025 | 40.08 | 27.07% |
| 2024 | 31.54 | -40.72% |
| 2023 | 53.21 | -13.69% |
| 2022 | 61.65 | -5.96% |
| 2021 | 65.55 | 53.10% |
| 2020 | 42.82 | 5.75% |
| 2019 | 40.49 | -57.30% |
| 2018 | 94.81 | 161.10% |
| 2017 | 36.31 | 242.94% |
| 2016 | 10.59 | -43.89% |
| 2015 | 18.87 | -6.23% |
| 2014 | 20.13 | 81.79% |
| 2013 | 11.07 | -19.98% |
| 2012 | 13.84 | -24.64% |
| 2011 | 18.36 | -2.69% |
| 2010 | 18.87 | -36.40% |
| 2009 | 29.66 | 230.95% |
| 2008 | 8.96 | -61.80% |
| 2007 | 23.47 | -4.11% |
| 2006 | 24.47 | 25.37% |
| 2005 | 19.52 | -33.99% |
| 2004 | 29.57 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -72.40% |
US
|
|
| -28.36 | -127.19% |
US
|
|
| -24.57 | -123.56% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -70.92% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.